Management

Abstract

CAR-T therapy is a promising treatment for B-cell malignancies but is also associated with toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Frequent monitoring, timely recognition and prompt management in ICU are paramount to ensure good outcomes.